Replimune Group Stock
Replimune Group, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Sushil Patel
- Employees
- 465
- Market cap
- $1 B
- IPO
- 20/07/2018
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against…
Replimune Group stock: price history
1D
-7.6%
1W
-19.1%
1M
-16.2%
6M
+400.5%
YTD
+11.7%
1Y
+132.5%
2Y
-4.8%
5Y
-64.0%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~32% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Replimune Group stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 08/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Replimune Group Inc is a biotechnology company specializing in the development of oncolytic immuno-gene therapies for the treatment of various cancer types. The company utilizes a proprietary immunotherapy platform to develop novel therapeutic candidates designed to selectively activate the body's immune system against malignant cells. Key drug candidates include RP1, a selectively replicating derivative of herpes simplex virus 1, which is currently in clinical Phase I/II trials. Additionally, candidates RP2 and RP3 are being developed to modulate immune response or stimulate T cells. The business model is currently primarily focused on the research and development phase of clinical trials.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Weak
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Replimune Group
Analyst assessment of Replimune Group
PRICE TARGET LOW
US$17.00
CONSENSUS
US$18.67
MEDIAN
US$19.00
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
11
BUY
3
HOLD
1
SELL
0
STRONG SELL
15
TOTAL · Buy
As of: 26/08/2026
Replimune Group stock metrics
P/E
-3.45
P/B
9.96
EV/EBITDA
-3.31
RETURN ON EQUITY
-66.0%
NET MARGIN
0.0%
DEBT/EQUITY
1.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
94.1%
FLOAT SHARES
88,613,534
AVG. DAILY VOLUME (30D)
2,053,790
Insider transactions (SEC)
Astley-Sparke Philip
Hill Emily Luisa
Schwendenman Andrew
Patel Sushil
Hill Emily Luisa
Attention
Price since yesterday: -7.6%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about Replimune Group stock
What does Replimune Group do?
Replimune Group, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Sushil Patel, the company employs around 465 people.
The IPO was on 20/07/2018; the stock trades on NASDAQ under the ticker REPL.
What do analysts say about Replimune Group stock?
15 analysts rate the stock, the consensus is Buy (as of 26/08/2026).
The average price target is US$18.67, ranging from US$17.00 to US$20.00, with a median of US$19.00.
This is an external assessment, not a statement by Market Jury.
When does Replimune Group report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -32% stronger than usual.
Does Replimune Group pay a dividend?
No, Replimune Group currently does not pay a dividend.
Which stocks are comparable to Replimune Group?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Replimune Group stock analyzed?
Clicking "Analyze stock" lets five strategies assess Replimune Group against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.